Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

Launched by BEIJING CHAO YANG HOSPITAL · Jan 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with left-sided obstructive colonic cancer. The researchers want to see if combining a medication called Camrelizumab, which helps the body's immune system fight cancer, with chemotherapy (medication that targets cancer cells) after using a stent (a small tube placed to relieve blockage) can improve survival rates. The goal is to provide better outcomes for patients who may face complications from emergency surgery, which can have high risks and often leads to permanent changes like a stoma (an opening in the abdomen for waste).

To be eligible for the trial, participants must have a confirmed blockage in the left colon or upper rectum due to cancer and be able to provide consent. They should also have a resectable tumor, meaning it can be surgically removed, and meet certain health criteria, like having adequate blood counts and liver function. If enrolled, participants will receive the combination treatment and will be monitored to see if it helps improve their chances of successful surgery and overall health. This trial is currently recruiting patients and aims to provide valuable information on how to better manage this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma
• • Able to give written, informed consent
• • Primary tumor was resectable
• • ECOG score 0 or 1
• • Haemoglobin greater than 100 g/L after transfusion before chemotherapy,
• • White blood cells greater than 3.0×10# /L
• • Platelets greater than 100×10# / L;
• • Glomerular filtration rate greater than 50 mL per minute as calculated by the Wright or Cockroft formula
• • Bilirubin less than 1.5×Upper Limit of Normal(ULN)
• • ALT and AST less than 2.5×ULN
• Exclusion Criteria:
• • Distal rectal cancers(equal or less than 10cm from the anal verge)
• • Patients with signs of peritonitis and/or bowel perforation
• • Patients who did not give informed consent
• • Patients who were considered unfit for operative treatment or refuse surgery.
• • Patients with suspected or proven metastatic adenocarcinoma;
• • Patients with unresectable colorectal cancer, or planning for palliative treatment.